Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients

AIM: To assess the benefit of rituximab with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-DA-EPOCH) regimen as a first-line treatment for patients with diffuse large B-cell lymphoma (DLBCL) presenting with unfavorable or aggressive features, and autologous s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Croat Med J
Main Authors: Pejša, Vlatko, Prka, Željko, Lucijanić, Marko, Mitrović, Zdravko, Piršić, Mario, Jakšić, Ozren, Ajduković, Radmila, Kušec, Rajko
Formato: Artigo
Idioma:Inglês
Publicado em: Croatian Medical Schools 2017
Assuntos:
Clinical Science
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5346894/
https://ncbi.nlm.nih.gov/pubmed/28252874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3325/cmj.2017.58.40
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados